𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Psychosocial outcome in a randomized surgical trial for treatment of primary breast cancer

✍ Scribed by M. Margaret Kemeny; David K. Wellisch; Wendy S. Schain

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
628 KB
Volume
62
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A randomized controlled trial of weight
A randomized controlled trial of weight reduction as a treatment for breast cancer-related lymphedema
✍ Clare Shaw; Peter Mortimer; Patricia A. Judd πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

## Abstract ## BACKGROUND. Obesity is considered a risk factor for the development of breast cancer‐related lymphedema of the arm and as a poor prognostic factor in response to lymphedema treatment. The objective of this study was to examine weight reduction as a treatment for breast cancer‐relate

Taxanes as primary chemotherapy for earl
Taxanes as primary chemotherapy for early breast cancer : Meta-analysis of randomized trials
✍ Federica Cuppone; Emilio Bria; Paolo Carlini; Michele Milella; Alessandra Felici πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 188 KB

## Abstract ## BACKGROUND. In patients with locally advanced and operable breast cancer, neoadjuvant chemotherapy has been demonstrated to increase the chance of breast‐conserving surgery (BCS) when compared with adjuvant treatment; moreover, patients who achieve a pathologic complete response (pC

A prospective randomized trial of doxoru
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer
✍ Massimo Lopez; Alma Contegiacomo; Patrizia Vici; Concetta Dello Ioio; Luigi Di L πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 481 KB πŸ‘ 2 views

Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who received DX trea